Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
The validations confirm the completion of the applications and commence the scientific review process
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The money will be donated to the United Nations Children’s Fund (UNICEF)
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)